Compass Therapeutics Investor Presentation Deck
CTX-8371 Pre-Clinical Poof of Concept
Activity in MC38-hPD-L1 model implanted in hPD-1/hPD-L1 transgenic mice
Average Tumor Volume (mm³)
1500-
1000-
500-
2000-
1500-
1000-
15
500-
IgG1 IC
Atezolizumab
2000₁
1500-
JIL
1000-
500-
10 20 30 40 50
18
21
27
24
Days after tumor cells inoculation
Endpoint
Responders
COMPASS
THERAPEUTICS
HHHH
0/8
0-
0 10 20 30 40 50
НА НЕН
IgG1 IC
Atezolizumab
→ KeytrudaⓇ
CTX-8371
30
20001
1500-
1000
500
CTX-8371
0-
0 10 20 30 40 50
Days post treatment
2000
1500-
1000-
500-
Keytruda Ⓡ
0 10 20 30 40 50
%Tumor Growth Inhibition [
100-
50-
-200
-400-
***
Mann-Whitney test
IgG1 IC
Group
CTX-8371
Atezolizumab
IgG1 IC
Keytruda
CTX-8371
** p=0.0001
* p=0.027
% Cured
62.5
KeytrudaⓇ Atezolizumab
12.5
0
25
Tumor free / total
5/8
1/8
0/8
2/8
36View entire presentation